Skip to main content
Smart Investors Daily
PL

NASDAQ · PLRX

Pliant Therapeutics, Inc.

Healthcare · Biotechnology

$0.70

Down-$0.00 (-0.55%)

Updated Nov 17, 2026, 1:19 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
80.8M
P/E ratio
-0.46
Dividend yield
0.00%
52-week range
$0.69 – $1.82
Volume
877.13K
Avg. volume
1.08M

Price performance · PLRX

PLRX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

PLRX closed at $0.70 after 20 trading sessions, down 22.44% for the selected period.

Last close
$0.70
Period change
-22.44%
Period low
$0.70
Period high
$0.91
Daily close
View OHLC price history
PLRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$0.74$0.754$0.69$0.697877.13K
Nov 12, 2026$0.775$0.775$0.7327$0.74525.31K
Nov 11, 2026$0.7862$0.7862$0.76$0.7776270.14K
Nov 10, 2026$0.82$0.82$0.77$0.7857360.59K
Nov 9, 2026$0.8056$0.8367$0.7901$0.7996288.55K
Nov 6, 2026$0.8094$0.8235$0.8009$0.8097151.62K
Nov 5, 2026$0.85$0.85$0.7951$0.8158340.32K
Nov 4, 2026$0.86$0.8823$0.8416$0.8518205.29K
Nov 3, 2026$0.8352$0.8641$0.8351$0.8607148.54K
Nov 2, 2026$0.85$0.8554$0.8388$0.8392385.68K
Oct 30, 2026$0.856$0.8825$0.84$0.8589169.52K
Oct 29, 2026$0.875$0.903$0.851$0.86205.95K
Oct 28, 2026$0.857$0.8898$0.845$0.8898118.18K
Oct 27, 2026$0.842$0.8819$0.8303$0.8571346.68K
Oct 26, 2026$0.8668$0.899$0.8367$0.8498298.92K
Oct 23, 2026$0.87$0.879$0.831$0.8636446.82K
Oct 22, 2026$0.90$0.90$0.851$0.8653289.8K
Oct 21, 2026$0.9271$0.928$0.88$0.8858340.62K
Oct 20, 2026$0.9026$0.94$0.8963$0.9124319.69K
Oct 19, 2026$0.9127$0.928$0.875$0.8987292.31K

Latest PLRX news

The latest Smart Investors Daily articles mentioning PLRX.

PLRX research

Overview

Company profile and research snapshot.

Company profile

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$31.14
Implied upside
—
Analysts
—
PLRX recent ratings
DateFirmRatingTarget
Mar 13, 2026Canaccord GenuityHold—
Mar 12, 2026Piper SandlerOverweight—
Nov 7, 2025RBC CapitalSector Perform—
Oct 10, 2025JP MorganUnderweight—
Aug 8, 2025Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment Pliant’s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical results Strengthened leadership team with appointments of David Raben, M.D., as Chief Medical Officer and Craig Blanchette, Ph.D., as Senior Vice President, Research (RNAi) SOUTH SAN FRANCISCO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinica

Yahoo · Nov 9, 2026

Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related to PLN-101095 at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Poster Presentations Title: Selective targeting of integrins αvβ8 and αvβ1 improves anti-tumor responses mediated by immune checkpoint inhibition Nika Rajabian, Ph.D., Postdoctoral Fellow f

Yahoo · Oct 29, 2026

Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 - 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona. Poster Presentations Title: Selective targeting of in

Yahoo · Oct 20, 2026

Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)

Craig D. Blanchette, Ph.D. Dr. Blanchette is a recognized leader in RNAi drug discovery and development was appointed Senior Vice President, Research (siRNA) of Pliant Therapeutics. Recognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company’s integrin-mediated delivery platform SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focus

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.